Cian Healthcare Limited has achieved a major milestone in its corporate restructuring journey with the receipt of key approvals from BSE Limited dated March 10, 2026. The approvals encompass both equity share issuance to new promoters and listing permissions for public shareholders, marking progress in the implementation of the NCLT-approved resolution plan.

BSE Approvals Received

The company disclosed receiving two critical approvals from BSE Limited under Regulation 30 of SEBI Listing Regulations:

Promoter Structure and Shareholding

The in-principle approval covers equity share allocation to three prospective promoters under the resolution plan:

The newly allotted equity shares will rank pari-passu with existing equity shares, including dividend and voting rights. Mr. Pradeep Kumar Jain serves as the Successful Resolution Applicant who submitted the approved resolution plan under the Insolvency and Bankruptcy Code, 2016.

Implementation Timeline and Compliance

The company will proceed with share allotment upon completing applicable compliance requirements and fulfilling conditions stipulated in BSE's approval letter. For the 12,50,000 shares approved for listing, these were previously allotted in the Resolution Plan Implementation Committee meeting held on January 23, 2026.

BSE has specified that listing applications must be submitted within twenty days from the date of allotment, as per SEBI circular dated June 21, 2023. The company must complete requisite trading formalities and credit shares to respective demat accounts of public shareholders.

Regulatory Framework

The approvals align with multiple regulatory frameworks including SEBI Master Circular dated January 30, 2026, and provisions under the Companies Act, 2013, Securities Contracts Regulation Act, 1956, and SEBI LODR Regulations, 2015. The company has committed to keeping stakeholders and regulatory authorities informed of further material developments in the resolution plan implementation process.

Cian Healthcare Limited has restructured its board governance following the completion of insolvency resolution proceedings. The company announced the constitution of three new board committees on February 09, 2026, marking a significant milestone in its corporate reorganization under the Insolvency and Bankruptcy Code, 2016.

The board of directors passed resolutions by circulation on February 09, 2026 at 06:06 P.M., approving the formation of mandatory board committees as required under regulatory provisions. This development follows the National Company Law Tribunal's approval of the resolution plan on December 18, 2025, submitted by the successful resolution applicant, Mr. Pradeep Kumar Jain.

Board Committee Structure

The company has established three essential committees to ensure compliance with the Companies Act, 2013, and SEBI listing regulations. The restructuring became necessary following the deemed resignation of erstwhile directors and the dissolution of previous committees as mandated by the NCLT order.

Committee Composition Details

The newly formed committees demonstrate a balanced governance structure with independent directors taking key leadership positions:

Regulatory Compliance Framework

The committee formation aligns with multiple regulatory requirements, including Section 177 and Section 178 of the Companies Act, 2013, along with SEBI listing regulations. The company has also complied with the SEBI Master Circular dated January 30, 2026, ensuring adherence to updated governance norms.

The Stakeholders' Relationship Committee will oversee investor grievances and stakeholder communications, while the Audit Committee will monitor financial reporting and internal controls. The Nomination and Remuneration Committee will handle board appointments and compensation policies, ensuring transparent governance practices.

Post-Resolution Corporate Structure

The successful completion of the insolvency resolution process under Mr. Pradeep Kumar Jain's leadership has enabled the company to establish a fresh governance framework. The inclusion of two independent directors, Mr. Manish Goswami and Mr. Anjani Misra, strengthens the board's independence and oversight capabilities.

This committee restructuring represents a crucial step in Cian Healthcare's corporate revival, providing the necessary governance infrastructure to support future business operations and regulatory compliance.